Daniel Associates

Hemato Oncology Testing Market by Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) & Region – Global Forecast to 2024

  • The Hemato Oncology Testing market was valued at USD XX Billion in 2018 and is estimated to reach USD XX Billion by 2024, at a CAGR of XX% during the forecast period. The base year used for this study is 2018, and the forecast period considered is between 2019 and 2024.

    The objectives of the study are as follows:

    • To define, describe, and forecast the Hemato Oncology Testing market segmented By Product & Services (Assay Kits, Services), Cancer (Leukemia (Acute Lymphoblastic, Acute Myeloid), Non-Hodgkin’s Lymphoma), Technology (PCR, NGS, IHC), End-User (Clinical Laboratories, Hospitals) & Region
    • To forecast the market size in terms of value for various segments with respect to four main regions: North America, Europe, APAC, and Latin America and MEA
    • To provide detailed information regarding the major factors influencing the growth of the Hemato Oncology Testing market (drivers, restraints, opportunities, and industry-specific challenges)
    • To provide a detailed overview of the value chain in the Hemato Oncology Testing market and analyze the market trends with Porter’s five forces analysis
    • To analyze the opportunities in the market for various stakeholders by identifying the high-growth segments of the Hemato Oncology Testing market
    • To strategically profile the key players and comprehensively analyze their market position in terms of ranking and core competencies, along with detailing the competitive landscape for the market leaders
    • To analyze competitive developments such as new product launches and developments; agreements and contracts; mergers and acquisitions; and expansions in the global Hemato Oncology Testing market

    The years considered for the study are:

    Base Year – 2018         Estimated Year – 2019         Forecast Period – 2024

    For company profiles in the report, 2018 has been considered as the base year. In certain cases, wherein information is unavailable for the base year, the years prior to it have been considered

    Market Segmentation,

    Hemato Oncology Testing Market, Based on Product & Service

    Services

    Assay Kits

    Hemato Oncology Testing Market, Based on Cancer Type

    Leukemia

       Acute myeloid leukemia

       Acute lymphocytic leukemia

       Other leukemia

    Lymphoma

       non-Hodgkin’s Lymphoma

       Hodgkin’s Lymphoma

       Other cancers

    Hemato Oncology Testing Market, Based  on Technology

    PCR

    IHC

    NGS

    Cytogenetics

    Others

    Hemato Oncology Testing Market, Based on End User 

    Clinical laboratories

    Hospitals

    Academic & Research Institutes

    Other End Users

    Hemato Oncology Testing Market, Based on Region:

    Asia-Pacific

    North America

    Europe

    Latin America

    Middle East & Africa

  • Table of Contents

    1 Introduction

    2 Research Methodologies

    3 Executive Summaries

    4 Premium Insights
    4.1 Hemato-Oncology Testing: Market Overview
    4.2 Hemato-Oncology Testing Market, By Product & Service
    4.3 Hemato-Oncology Testing Market, By Cancer Type
    4.4 Hemato-Oncology Testing Market, By Technology
    4.5 Hemato-Oncology Testing Market, By End User

    5 Market Overview
    5.1 Introduction
    5.2 Market Dynamics
    5.2.1 Drivers
    5.2.2 Opportunities
    5.2.3 Restraints
    5.2.4 Challenges

    6 Hemato-Oncology Testing Market, By Product & Service
    6.1 Introduction
    6.2 Services
    6.3 Assay Kits

    7 Hemato-Oncology Testing Market, By Cancer Type
    7.1 Introduction
    7.2 Leukemia
    7.2.1 Acute Myeloid Leukemia
    7.2.2 Acute Lymphocytic Leukemia
    7.2.3 Other Leukemias
    7.3 Lymphoma
    7.3.1 Non-Hodgkin Lymphoma
    7.3.2 Hodgkin Lymphoma
    7.4 Other Cancers

    8 Hemato-Oncology Testing Market, By Technology
    8.1 Introduction
    8.2 PCR
    8.3 IHC
    8.4 NGS
    8.5 Cytogenetics
    8.6 Other Technologies

    9 Hemato-Oncology Testing Market, By End User
    9.1 Introduction
    9.2 Clinical Laboratories
    9.3 Hospitals
    9.4 Academic & Research Institutes
    9.5 Other End Users

    10 Hemato-Oncology Testing Market, By Region
    10.1 Introduction
    10.2 North America
    10.3 Europe
    10.4 Asia Pacific
    10.5 Middle East & Africa

    11 Competitive Landscape

    12 Company Profiles
    (Business Overview, Financials, Products & Services, Recent Developments)*
    12.1 F. Hoffman-La Roche Ltd.
    12.2 Abbott Laboratories
    12.3 Qiagen N.V.
    12.4 Thermo Fisher Scientific, Inc.
    12.5 Illumina, Inc.
    12.6 Bio-Rad Laboratories, Inc.
    12.7 Molecularmd (Subsidiary of Icon PLC)
    12.8 Archerdx, Inc.
    12.9 Arup Laboratories Inc.
    12.10 Asuragen, Inc.
    12.11 Invivoscribe, Inc.
    12.12 Adaptive Biotechnologies.

    *Details Might Not Be Captured in Case of Unlisted Companies.



  • Select User License